At Longeveron, Dr. Joshua Hare and his team are working on an Alzheimer’s treatment using human-derived bone marrow ...

The UK is studying cases of pancreatitis in people taking drugs based on GLP-1 receptor agonists for weight loss or type 2 ...

An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first ...

The licensing deal for BAFF/APRIL inhibitor telitacicept, which also includes regulatory and commercial milestones exceeding ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

As the CEO of ProofPilot, Chris Venezia has a track record of success with more than 18 years of strong leadership in product commercialisation, patient recruitment, marketing, and sales. He joined ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.

Jennifer Goldsack of DiME talks in this podcast about the ROI for digital endpoints for pharma. Data shows digital endpoints drives meaningful engagement with healthcare providers.

Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector, but has new data that could tip the balance in its favour. The results of the first head-to-head trial of ...

Autolus' CAR-T cell therapy for a rare and aggressive form of acute lymphoblastic leukaemia (ALL), Aucatzyl, has been recommended for conditional approval in the EU.